CureVac

Operating from its headquarters in Tübingen, Germany, and additional sites across Europe and the U.S., CureVac has dedicated over two decades to refining its mRNA platform. The company's business model is centered on the research, development, and commercialization of a new class of therapies and vaccines. It operates in the global biotechnology market, with a focus on oncology, prophylactic vaccines, and molecular therapies. CureVac generates revenue through strategic partnerships with pharmaceutical companies and by advancing its proprietary product candidates through clinical development towards commercialization.

The company's product pipeline includes clinical and preclinical programs in several areas. In oncology, CureVac is developing off-the-shelf and personalized cancer vaccine candidates designed to elicit a specific anti-tumor response. Its work in prophylactic vaccines extends beyond its foundational contributions to COVID-19 vaccine technology to address other infectious diseases. Furthermore, CureVac is developing therapies that enable the body to produce its own therapeutic proteins, potentially treating a wide range of diseases.